A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

MLA

Jean-François Augusto, et al. A Regimen with Caplacizumab, Immunosuppression, and Plasma Exchange Prevents Unfavorable Outcomes in Immune-Mediated TTP. Feb. 2021. EBSCOhost, https://doi.org/10.1182/blood.2020008021⟩.

APA

Jean-François Augusto, Naïke Bigé, Lionel Galicier, Alain Wynckel, Nihal Martis, Michael Bubenheim, Ygal Benhamou, Antoine Dossier, Claire Presne, Elie Azoulay, Virginie Rieu, Agnès Veyradier, Sandrine Malot, François Provôt, Christelle Barbet, Miguel Hie, Amélie Seguin, Sten de Witte, Pascale Poullin, … Olivier Moranne. (2021). A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. https://doi.org/10.1182/blood.2020008021⟩

Chicago

Jean-François Augusto, Naïke Bigé, Lionel Galicier, Alain Wynckel, Nihal Martis, Michael Bubenheim, Ygal Benhamou, et al. 2021. “A Regimen with Caplacizumab, Immunosuppression, and Plasma Exchange Prevents Unfavorable Outcomes in Immune-Mediated TTP,” February. doi:10.1182/blood.2020008021⟩.